Related Experiment Video
Updated: Jul 14, 2026
07:17
Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
Published on: August 23, 2024
Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications
Kieron Dunleavy1, Wyndham H Wilson, Elaine S Jaffe
1Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Current Opinion in Hematology
|May 31, 2007
Summary
Angioimmunoblastic T cell lymphoma (AITL) involves Epstein-Barr virus and B cell issues. New therapies targeting follicular helper T cells and angiogenesis show promise for this challenging lymphoma.
Area of Science:
- Immunology
- Oncology
- Hematology
Background:
- Angioimmunoblastic T cell lymphoma (AITL) is a complex lymphoproliferative disorder.
- The roles of Epstein-Barr virus and B cell dysregulation in AITL pathogenesis are not fully understood.
- Traditional chemotherapy offers a poor prognosis for AITL patients.
Purpose of the Study:
- To review recent findings in AITL pathobiology.
- To discuss novel therapeutic strategies for AITL.
- To highlight the potential of understanding AITL for broader immunology insights.
Main Methods:
- Analysis of gene-expression profiling in neoplastic cells.
- Investigation of chemokine and growth factor overexpression.
- Review of emerging immunomodulatory and anti-angiogenic therapies.
Main Results:
- Neoplastic cells in AITL overexpress CXCL13, suggesting follicular helper T cell origin.
- Gene-expression profiling confirms follicular helper T cell characteristics.
- High expression of vascular endothelial growth factor-A is noted, with promising early results for bevacizumab.
Conclusions:
- AITL research advances our understanding of the normal immune system.
- Significant progress in elucidating AITL biology has been achieved.
- New therapeutic strategies, including immunomodulation (cyclosporine) and angiogenesis inhibition (bevacizumab), show promise.
